Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...

BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...

2025 is shaping up to be a big year for BBI Brands. The entire family of BBI Brands – including BBI Transportation and BBI Real Estate – is almost completely moved into the new office space at Astor ...

FORT LAUDERDALE, Fla., Nov. 4, 2025 /PRNewswire/ -- Burdette Beckmann Inc. (BBI), a national sales agency leader in the confectionery industry, is proud to announce the acquisition of Action Sales ...

Boundless Bio, a clinical-stage oncology company, announced its financial results for the first quarter of 2025, highlighting its ongoing commitments to developing innovative therapies for patients ...

Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the company to lay off one-third of its staff and pivot to a combination of two ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min BBI Logistics is a ...

An Atlanta development firm is moving forward on plans to build a massive town center in South Fulton with six new office buildings, three hotels and more than 1,000 apartments, a project that had ...

MCKINNEY, Texas--(BUSINESS WIRE)--ScienceSoft released proprietary research exploring the potential of behavior-based insurance (BBI) in life and health plans. Supported by statistical sources, ...